2 not yet recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
Follow HER2: new trials by email Literature Review of HER2 trials Research Report on HER2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations Almonertinib, Trastuzumab Rezetecan - Lung Cancer (NSCLC), EGFR Activating Mutation | Phase 2 | Not yet recruiting | Yongsheng Wang | 35 | 2026-09-09 | 2026-08-17 |
| MA-CRC-II-016 SHR-1811 SHR-A1811 & Bevacizumab injection, Chemotherapeutic Combinations - mCRC, HER2 | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 80 | 2025-12-30 | 2026-01-21 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Bevacizumab (1) · Drug Therapy (1) · aumolertinib (1)
Peking Union Medical College Hospital (1) · Yongsheng Wang (1)